Assignee
IMCLONE SYSTEMS INC
US·22 granted patents·15 pending applications·1,162 citations·filing 1991–2009
Top patents by PatentIndex Score
37 records- 0196US7498414B2Human antibodies specific to KDR and uses thereofIMCLONE SYSTEMS INC·Filed 2003·Granted Mar 3, 2009·98 cites·53 claims
- 0295US7060808B1Humanized anti-EGF receptor monoclonal antibodyIMCLONE SYSTEMS INC·Filed 1996·Granted Jun 13, 2006·167 cites·24 claims
- 0395US6811779B2Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapyIMCLONE SYSTEMS INC·Filed 2001·Granted Nov 2, 2004·99 cites·27 claims
- 0494US6365157B2Monoclonal antibodies specific to VEGF receptors and uses thereofIMCLONE SYSTEMS INC·Filed 1999·Granted Apr 2, 2002·133 cites·17 claims
- 0592US5840301AMethods of use of chimerized, humanized, and single chain antibodies specific to VEGF receptorsIMCLONE SYSTEMS INC·Filed 1994·Granted Nov 24, 1998·110 cites·40 claims
- 0691US5955311AMonoclonal antibodies specific to VEGF receptors and uses thereofIMCLONE SYSTEMS INC·Filed 1998·Granted Sep 21, 1999·83 cites·8 claims
- 0791US5874542ASingle chain antibodies specific to VEGF receptorsIMCLONE SYSTEMS INC·Filed 1997·Granted Feb 23, 1999·79 cites·12 claims
- 0889US6448077B1Chimeric and humanized monoclonal antibodies specific to VEGF receptorsIMCLONE SYSTEMS INC·Filed 1997·Granted Sep 10, 2002·53 cites·38 claims
- 0987US6852321B2Lectin-derived progenitor cell preservation factor and methods of useIMCLONE SYSTEMS INC·Filed 2001·Granted Feb 8, 2005·25 cites·16 claims
- 1084US5846709AChemical process for amplifying and detecting nucleic acid sequencesIMCLONE SYSTEMS INC·Filed 1993·Granted Dec 8, 1998·116 cites·26 claims
- 1182US5861499ANucleic acid molecules encoding the variable or hypervariable region of a monoclonal antibody that binds to an extracellular domainIMCLONE SYSTEMS INC·Filed 1996·Granted Jan 19, 1999·53 cites·8 claims
- 1273US6280724B1Composition and method for preserving progenitor cellsIMCLONE SYSTEMS INC·Filed 1999·Granted Aug 28, 2001·36 cites·29 claims
- 1370US7112653B2Composition and method for preserving progenitor cellsIMCLONE SYSTEMS INC·Filed 2003·Granted Sep 26, 2006·4 cites·15 claims
- 1470US6310195B1Nucleic acid encoding a lectin-derived progenitor cell preservation factorIMCLONE SYSTEMS INC·Filed 1997·Granted Oct 30, 2001·22 cites·17 claims
- 1568US5547670ARecombinant hybrid porin epitopesIMCLONE SYSTEMS INC·Filed 1993·Granted Aug 20, 1996·26 cites·4 claims
- 1665US7371574B2Antibody antagonists of VE-cadherin without adverse effects on vascular permeabilityIMCLONE SYSTEMS INC·Filed 2002·Granted May 13, 2008·2 cites·11 claims
- 1765US2009099339A1Antibody and antibody fragments for inhibiting the growth of tumorsIMCLONE SYSTEMS INC·Filed 2008·Application pending·0 cites
- 1864US6084060AComposition and method for preserving progenitor cellsIMCLONE SYSTEMS INC·Filed 1997·Granted Jul 4, 2000·24 cites·18 claims
- 1962US2005060779A1Lectin-derived progenitor cell preservation factors and methods of useIMCLONE SYSTEMS INC·Filed 2004·Application pending·0 cites
- 2061US2008311121A1Antibody antagonists of ve-cadherin without adverse effects on vascular permeabilityIMCLONE SYSTEMS INC·Filed 2008·Application pending·0 cites
- 2161US2008317750A1Antibody antagonists of ve-cadherin without adverse effects on vascular permeabilityIMCLONE SYSTEMS INC·Filed 2008·Application pending·0 cites
- 2261US2009060909A1Antibody antagonists of ve-cadherin without adverse effects on vascular permeabilityIMCLONE SYSTEMS INC·Filed 2008·Application pending·0 cites
- 2361US2009022716A1Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonistIMCLONE SYSTEMS INC·Filed 2007·Application pending·0 cites
- 2459US2009022714A1Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonistIMCLONE SYSTEMS INC·Filed 2006·Application pending·0 cites
- 2553US5359034ACysteine depleted IL-6 muteinsIMCLONE SYSTEMS INC·Filed 1992·Granted Oct 25, 1994·15 cites·10 claims
- 2651US2009297509A1Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinasesIMCLONE SYSTEMS INC·Filed 2009·Application pending·0 cites
- 2750US6410723B1VDUP1 promoter and methods of use thereofIMCLONE SYSTEMS INC·Filed 2000·Granted Jun 25, 2002·0 cites·25 claims
- 2849US2009048301A1Heterocyclic compounds and their use as anticancer agentsIMCLONE SYSTEMS INC·Filed 2004·Application pending·0 cites
- 2949US2007274981A1Fibroblast Growth Factor Receptor-1 Inhibitors and Methods of Treatment ThereofIMCLONE SYSTEMS INC·Filed 2004·Application pending·0 cites
- 3047US2009306348A1Antibody FormulationIMCLONE SYSTEMS INC·Filed 2007·Application pending·0 cites
- 3147US2005181997A1Progenitor cell preservation factors and methods for and products of their useIMCLONE SYSTEMS INC·Filed 2005·Application pending·0 cites
- 3246US2008118480A1Methods and Compositions for Directing Migration of Neural Progenitor CellsIMCLONE SYSTEMS INC·Filed 2004·Application pending·0 cites
- 3344US5334532APDGF-B fusion protein, vectors, and host cells for use in production thereofIMCLONE SYSTEMS INC·Filed 1991·Granted Aug 2, 1994·9 cites·3 claims
- 3442US6613565B1Use of delta-like protein to inhibit the differentiation of stem cellsIMCLONE SYSTEMS INC·Filed 1997·Granted Sep 2, 2003·6 cites·16 claims
- 3541US2008171050A1Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonistsIMCLONE SYSTEMS INC·Filed 2007·Application pending·0 cites
- 3638US2009246205A1Inhibition of macrophage-stimulating protein receptor (ron)IMCLONE SYSTEMS INC·Filed 2005·Application pending·0 cites
- 3724US5501948AStabilized hepatitis B e antigen suitable for immunoassaysIMCLONE SYSTEMS INC·Filed 1994·Granted Mar 26, 1996·2 cites·12 claims
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →